Cilastatin Sodium/Imipenem/Relebactam

亚胺西瑞

Report date: 2026/02/06 20:01:23
QIDP

Base Information

Drug NameCilastatin Sodium/Imipenem/Relebactam
Drug Alias NameRelebactam/西司他丁钠/亚胺培南Relebactam/Cilastatin Sodium/ImipenemRelebactam/西司他丁/亚胺培南imipenem+cilastatin+relebactam瑞来巴坦/西司他丁钠/亚胺培南 +[10] 
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Carbapenems antibiotics
Mechanisms of ActionBeta Lactamase inhibitorsEnzymes inhibitorsBacterial penicillin-binding protein inhibitors
TargetsBeta LactamaseEnzymesBacterial penicillin-binding protein
Therapy Area/IndicationsHospital-acquired pneumoniaUrinary Tract InfectionsSepsis +[11] 
Global Approved IndicationsHospital-acquired pneumoniaUrinary Tract InfectionsIntraabdominal Infections +[6] 
Approved Indications in ChinaHospital-acquired pneumoniaPneumonia, Bacterial
Original Approved Country/TerritoryUnited States
Original Approved Date2019/07/16
Country/TerritoryBulgariaUnited StatesUkraine +[23] 
CombinationsYes Cilastatin SodiumImipenemRelebactam
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMds Co LtdMerck Sharp & Dohme CorpMerck Sharp & Dohme Bv +[6] 
Inactive CompaniesN/A
Active IndicationsHospital-acquired pneumoniaUrinary Tract InfectionsSepsis +[10] 
Inactive IndicationsBacterial Infections

Other Information

ATC CodeJ01CR
Related LinksWikipediaKEGG